Association of posterior reversible encephalopathy syndrome with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database.

• DOI: 10.1200/jco.2024.42.16_suppl.e19515
• Publication Date: 2024-06-10T18:45:04Z
• Authors: Harkarandeep Singh; Uttamjot Kaur; Niraj Neupane; Himal Kharel; Hassan Saeed; Prabhsimrat Gill; Asis Shrestha
• Keywords: 03 medical and health sciences; 0302 clinical medicine

e19515 Background: Proteasome inhibitors (PI) are a class of drugs that used in the treatment Multiple Myeloma. There currently three PIs (Bortezomib, Carfilzomib, and Ixazomib) approved by FDA for this indication. Peripheral neuropathy has been described as one their most common side effects but association with another life-threatening neurological disorder, Posterior Reversible Encephalopathy Syndrome (PRES), remains poorly understood. Methods: We conducted retrospective pharmacovigilance study using Adverse Event Reporting System database to analyze risk PRES associated various Inhibitors. employed disproportionality signal analysis calculated reporting odds ratio 95% confidence interval. Results: A total 79,450 adverse events were found within FAERS PIs. accounted 274 cases, which 165 cases females 71 males. Majority patients adults, 119 between 18-64 years age, 88 above 65 years, 50 age not specified. Death was reported 70 while 74 marked having life threatening illness, 152 needed hospitalization. Bortezomib (202 ROR 6.03, CI 5.3-7.1), followed Carfilzomib (68 7.2, 5.7-9.1), Ixazomib (9 0.99, 0.5-1.7). Conclusions: The helps shed light on incidence, hospital outcomes proteasome inhibitors. Significant safety signals Bortezomib, Carfilzomib. Females almost 2.5 times more likely develop compared These findings highlight importance keeping high index suspicion evaluating who present concerning symptoms.